The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
about
Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitorPhosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle controlPIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancersTargeting JAK2 in the therapy of myeloproliferative neoplasmsAconitase regulation of erythropoiesis correlates with a novel licensing function in erythropoietin-induced ERK signaling.Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinasesModulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode DependentTargeting Pim kinases for cancer treatment: opportunities and challengesThe PIM kinases in hematological cancersCharacterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancerSTAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutantNADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases.Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analysesActivation of JAK2-V617F by components of heterodimeric cytokine receptorsThe molecular regulation of Janus kinase (JAK) activationKinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolismBCR-JAK2 drives a myeloproliferative neoplasm in transplanted mice.Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutantThe thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasmFunctional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic responseThe JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activityCharacterization of Leukemia-Inducing Genes Using a Proto-Oncogene/Homeobox Gene Retroviral Human cDNA Library in a Mouse In Vivo Model.The Bone Marrow-Mediated Protection of Myeloproliferative Neoplastic Cells to Vorinostat and Ruxolitinib Relies on the Activation of JNK and PI3K Signalling Pathways.Efficacy of vorinostat in a murine model of polycythemia veraCrystal Structure of the FERM-SH2 Module of Human Jak2.Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in miceDistinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation.Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic TransformationJAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasmsLnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617FThe granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease.BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair.Eliminative signaling by Janus kinases: role in the downregulation of associated receptors.Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.
P2860
Q21142745-406B1E47-0909-4038-8487-20113EDBFDD6Q24297854-5DF0ED8F-8B1C-4301-B08B-ED7C17295334Q24603099-94DF1E92-094B-4881-95FC-2D9FB6B11FF1Q26860796-78223F32-7A18-48A3-974A-A8B03A608A5BQ27323049-E0DC4F21-CC92-4723-A099-7E8A1186F8AEQ27679885-DEDF7FB5-5728-49F8-AB40-743281D6E96FQ27681086-D0CFD088-DF7F-4F14-BE69-397D71E60459Q28255361-3D873BEF-242D-4F48-9006-36A9B8C1EDC6Q28258028-EA670CF0-564A-4B3A-9214-98FB824914F6Q28830328-FF103415-8332-4413-90CB-1E3E94CEDAABQ33648325-33199793-A293-4B7C-9FCC-CD81FBD398B8Q33834313-E76F4EF8-F08E-426A-8AB8-7A6F4F87CFA9Q33857008-F5F2F406-FDEA-46B3-B4C8-9DD9B3B3554EQ33883366-35529E31-40EF-4A15-BEBC-8266AEFA97C4Q33956113-4246BEFF-25BC-4E23-967E-80C9314EA632Q34021753-78E969CB-09F1-4D62-8063-4ED7B116A59DQ34186690-41DA49E6-D6C1-4EA6-AA84-60818CD4806CQ34461890-931F02DC-F36F-45DA-90C2-B3644872B308Q34542215-C40B4B4E-0AD7-40FB-9647-2A6B955BBEAFQ34737531-5D632950-FF34-4993-B576-D99DC73EBA59Q35072638-D47883E6-B502-467B-A87C-6F0A891B1DD8Q35163764-3399CBC3-2B96-42DF-BBCC-BE21507995EEQ35583247-B9B89DCC-7951-4B4A-B569-1C1053C124F9Q35852567-48F4B344-3868-4AAF-9C92-00D7F4BF8BE2Q35856790-0B04920C-58F2-46B1-AB30-0582372E9CC6Q35909673-B6EE426C-F790-45FB-8DFB-9282E48FCDF5Q36030099-DD4A6BBE-0023-49DC-A7A3-D19C5600A309Q36206435-5B404BC8-DF0A-4F0E-9802-A99B5CFE1388Q36323519-89ACACD0-6852-4CA9-9ACF-12DEE5B23AD2Q36359558-94C48A59-96FD-454A-84AD-A4C40521592CQ36545566-C1BA1151-63C1-4A59-BC5B-3A1DFA35B2FAQ36810315-0E34EDC7-3617-4E47-B9D1-7E8849FE174BQ36853951-DA3612A8-8D02-4C22-B0C0-3608483E1B46Q37168138-555F2F41-7CC9-4322-B998-B4599C1BFF50Q37232941-B57424A4-6527-4EB8-917A-5D9CBB6048CFQ37306641-45EBEE1D-B30B-4848-B9CE-286CE7C3B980Q37334605-EFA04E6F-10AB-43FC-AE1C-0C492AD7DACFQ37377109-21476F75-451C-41AD-AC7D-C4AA5A11AC57Q37460337-9942C43C-E682-4916-8DF4-8624BC7EFAE4Q37555785-A88D98C8-1987-4340-92C1-4F5899E23AEE
P2860
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
The Jak2V617F oncogene associa ...... he Myc and Pim proto-oncogenes
@ast
The Jak2V617F oncogene associa ...... he Myc and Pim proto-oncogenes
@en
type
label
The Jak2V617F oncogene associa ...... he Myc and Pim proto-oncogenes
@ast
The Jak2V617F oncogene associa ...... he Myc and Pim proto-oncogenes
@en
prefLabel
The Jak2V617F oncogene associa ...... he Myc and Pim proto-oncogenes
@ast
The Jak2V617F oncogene associa ...... he Myc and Pim proto-oncogenes
@en
P2093
P2860
P1433
P1476
The Jak2V617F oncogene associa ...... he Myc and Pim proto-oncogenes
@en
P2093
Andreas Reiter
Brian J Crowley
Christoph Walz
D Gary Gilliland
Gerlinde Wernig
Heidi E Hudon
James D Griffin
Jeffrey R Gonneville
Klaus Podar
Mamatha M Reddy
P2860
P304
P356
10.1182/BLOOD-2007-07-102186
P407
P577
2008-01-23T00:00:00Z